Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers

Exclusion Criteria

• •History of hypersensitivity or allergy to drug or food
• •History of clinically significant abnormalities such as metabolic, liver, kidney, blood, lung, cardiovascular, gastrointestinal, urinary, endocrine, neurological, or psychiatric disorders; or in the judgement of the investigator, any medical abnormality that may be a concern to participate the study.
• •Tympanic temperature \>37.5℃, Pulse \>100bmp or \<50bmp, Systolic blood pressure ≥140mHg or ≤90mHg, or Diastolic blood pressure ≥90mHg or\<50mHg
• •Clinically relevant out-of-range baseline of total white cells or absolute neutrophil count
• •Total bilirubin \>1.5x ULN, AST \>1.5 ULN or ALT \>1.5ULN
• •Estimated glomerular filtration rate (eGFR) \<90 mL/min/1.73 m2
• •QTc interval \> 450ms （ Fridericia's correction ， QTcF=QT/(RR\^0.33) ）, QRS\>120ms
• •Acute respiratory tract infection within 2 weeks
• •Any condition possibly affecting drug absorption, e.g. gastrectomy
• •Received treatment of any prescription drug or alternative medicine within 4 weeks before first dosing or any nonprescription drug within 2 weeks or 5x half-life, whichever is longer
• •Regular alcohol consumption \>14units/week I the past 6 months or positive in alcohol breath test
• •Use of tobacco or nicotine containing products more than the equivalent of 5 cigarettes per day within 3 months
• •Unwilling or unable to restrict the intake of caffeine or alcohol within 72 hours before dosing or during the in-patient observation period
• •Use or intake of any known liver enzyme inducer or inhibitor within 14 days
• •History of drug abuse or positive urine drug test
• •Positive test for Hepatitis C antibody (HCV), Hepatitis B surface antigen (HbsAg), Human immunodeficiency virus (HIV) antibody, or Syphilis antibody at Screening
• •Accumulative blood donation \>400ml within 3 months or \>200ml within 4 weeks or planning to donate during the study
• •Pregnancy or lactating at screening
• •Having difficulty of drawing blood from vein
• •Treatment with an investigational drug or procedure within 3 months
• •Received vaccination within 3 months or plan to be received vaccine during the study
• •Received any surgical procedure within 3 months at screening
• •Any other reason that, in the opinion of the investigator, unlikely to comply with the clinical study protocol or is unsuitable for any other reason.